作者
Francesco Sardanelli, Hildegunn S Aase, Marina Álvarez, Edward Azavedo, Henk J Baarslag, Corinne Balleyguier, Pascal A Baltzer, Vanesa Beslagic, Ulrich Bick, Dragana Bogdanovic-Stojanovic, Ruta Briediene, Boris Brkljacic, Julia Camps Herrero, Catherine Colin, Eleanor Cornford, Jan Danes, Gérard de Geer, Gul Esen, Andrew Evans, Michael H Fuchsjaeger, Fiona J Gilbert, Oswald Graf, Gormlaith Hargaden, Thomas H Helbich, Sylvia H Heywang-Köbrunner, Valentin Ivanov, Ásbjörn Jónsson, Christiane K Kuhl, Eugenia C Lisencu, Elzbieta Luczynska, Ritse M Mann, Jose C Marques, Laura Martincich, Margarete Mortier, Markus Müller-Schimpfle, Katalin Ormandi, Pietro Panizza, Federica Pediconi, Ruud M Pijnappel, Katja Pinker, Tarja Rissanen, Natalia Rotaru, Gianni Saguatti, Tamar Sella, Jana Slobodníková, Maret Talk, Patrice Taourel, Rubina M Trimboli, Ilse Vejborg, Athina Vourtsis, Gabor Forrai
发表日期
2017/7
期刊
European radiology
卷号
27
页码范围
2737-2743
出版商
Springer Berlin Heidelberg
简介
Abstract
EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40 % for women aged 50–69 years taking up the invitation while the probability of false-positive needle biopsy is <1 % per round and overdiagnosis is only 1–10 % for a 20-year screening. Mortality reduction was also observed for the age groups 40–49 years and 70–74 years, although with “limited evidence”. Thus, we firstly recommend biennial screening mammography for average-risk women aged 50–69 years; extension up to 73 or 75 years, biennially, is a second priority, from 40–45 to 49 years, annually, a third priority. Screening with thermography or other optical tools as alternatives to mammography is …
引用总数
20162017201820192020202120222023202411622373841342119